John Mendlein, CEO and Director at aTYR PHARMA INC (LIFE), bought 2,500 shares at $3.55 ($9K) on 2016-04-05, disclosed to the SEC on 2016-04-06.
Open-market purchase of $9k LIFE by CEO and Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Clearly above the average filing.
| Filing → |
| FATE | SELL | 2022-03-11 | $2.2M | — | Filing → |
| LIFE | BUY | 2018-12-26 | $102K | — | Filing → |
| LIFE | BUY | 2017-09-05 | $200K | — | Filing → |